THERAPY DOSSIER · th-b0bb3d4cba0a

Engineered zinc-finger protein transcription factor transactivator targeting vascular endothelial growth factor A, delivered by adenoviral vector or adeno-associated vector serotype 2

Other

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23016562 ↗2012Reported benefit

Treatment of traumatic brain injury using zinc-finger protein gene therapy targeting VEGF-A.

RatTBIFluid percussionSprague-DawleyMaleIntracerebral microinjectionAfter fluid percussion injury

Model: Unilateral fluid percussion injury of moderate severity at 2.2 to 2.5 atmospheres

Adenoviral VEGF zinc-finger protein reduced TUNEL-positive cells in the cortical penumbra and hippocampus at 72 h and improved CA1 field excitatory postsynaptic potentials, while adeno-associated vector delivery improved microvascular diameter and balance beam and rotarod performance at 30 days.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…